Skip to content

Ketamine for addiction: all studies

Page 8 of 15: studies 71 to 80 of 144, newest first. Back to the ketamine for addiction overview

Research

Ketamine Therapy in Patients of Alcohol Use Disorder: A Prospective Pilot Study to Evaluate Abstinence Rate with This Add-on Treatment Modality

Annals of Indian Psychiatry September 3, 2024 Nidhi Purushottum Marvania, Anto Leroy Rayan, Dhruti Vijaykumar Merchant et al. 3 citations

Background: Alcohol use disorders (AUDs) are emerging as a substance use disorder having various psychological and physical ill effects leading to hampering of individual’s productivity and functioning. Aims: The aim of this study was to evaluate the efficacy of ketamine in enhancing confidence levels to abstain from alcohol. Methods: Eighteen patients were administered ketamine intravenously...

Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.

Neuropharmacology September 1, 2024 Devin P Hagarty, Adam Dawoud, Alfonso Brea Guerrero et al. 6 citations

Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant Depression patients and repeated infusions are required to sustain its antidepressant properties. However, KET is an addictive drug, and so more preclinical and clinical research is needed to assess the safety of recurring treatments in both sexes....

DOI: 10.1016/j.neuropharm.2024.110008 (opens in new tab) Full text (opens in new tab) Dose-response Sex differences Cfos Addiction-risk +3

(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders.

International Journal of Molecular Sciences June 20, 2024 Hana Shafique, Julie C Demers, Julia Biesiada et al. 29 citations

NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine...

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.

Journal of Psychopharmacology June 1, 2024 Emily M Gent, Joshua W. Bryan, Maisy A Cleary et al. 20 citations

Alcohol use disorder (AUD) is a major public health issue, posing harmful consequences for individuals and society. Recent advances in addiction research have highlighted the therapeutic potential of ketamine-assisted therapy for AUD. However, the exact mechanisms underlying its effectiveness remain unknown. This double-blind, pilot study aimed to investigate esketamine combined with...

Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder.

Psychedelic Medicine June 1, 2024 Dale Terasaki 3 citations

Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have gained interest as potentially efficacious options, known to generate unique psychotherapeutic experiences. The present secondary analysis examines the acute subjective experiences-both...

DOI: 10.1089/psymed.2023.0066 (opens in new tab) Full text (opens in new tab) Alcohol use disorder Hospital-based treatment Hospitalization Ketamine therapy +3

A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.

The Journal of Clinical Psychiatry April 24, 2024 Gregory H Jones, Courtney M Vecera, Ana C Ruiz et al. 13 citations

Objective: Although individuals with a family history of alcohol use disorder (AUD) have a superior antidepressant response to ketamine, outcomes in patients with current AUD remain unclear. This study sought to investigate whether intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects in unipolar and bipolar depression and whether comorbid AUD conferred superior...

DOI: 10.4088/JCP.23m14974 (opens in new tab) Full text (opens in new tab) Depression Ketamine therapy Mental health treatment Substance abuse +1

Features of biliary tract diseases in ketamine abusers: a systematic review of case reports.

Journal of Medical Case Reports March 3, 2024 Alireza Teymouri, Hadis Nasoori, Maryamsadat Fakheri et al. 20 citations

Anesthesiologists prefer ketamine for certain surgeries due to its effectiveness as a non-competitive inhibitor of the N-methyl-D-aspartate receptor in the brain. Recently, this agent has also shown promise as an antidepressant. However, ketamine can cause hallucinogenic effects and is sometimes abused as an illicit drug. Ketamine abuse has been associated with liver and bile duct...

Ketamine in Substance Use Disorder Treatment: A Narrative Review.

Alpha psychiatry March 1, 2024 Anna Famuła, Jakub Radoszewski, Tomasz Czerwiec et al. 8 citations

Substance use disorder (SUD) continues to pose a significant global health challenge, necessitating innovative and effective therapeutic interventions. Ketamine, traditionally recognized for its anesthetic properties, has emerged as a novel and promising avenue for the treatment of SUD. This narrative review critically examines the current body of literature surrounding the use of ketamine in...

DOI: 10.5152/alphapsychiatry.2024.241522 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Alcohol dependence Addiction treatment Substance abuse recovery +1

Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats

Nature Communications January 30, 2024 Tommaso Di Ianni, Sedona N. Ewbank, Marjorie R. Levinstein et al.

Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N -methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of subanesthetic ketamine may...

Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood.

Frontiers in Pharmacology 2024 Carles Colom-Rocha, Cristian Bis-Humbert, M Julia García-Fuster 3 citations

Few studies have previously evaluated the long-term impact of initiating the combined use of alcohol and cocaine early-in-life during adolescence. Our preclinical study characterized changes in affective-like behavior and/or voluntary ethanol consumption emerging later on in adulthood induced by a prior adolescent drug exposure, as well as tested therapeutical interventions (i.e., cannabidiol...